Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 22, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that CEO John T. Hendrickson will present at the J.P. Morgan Global Healthcare Conference at 11:00 AM EST on Tuesday, January 10, 2017 at the...
-
Dec 20, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received approvals from the U.S. Food and Drug Administration for Abbreviated New Drug Applications referencing GlaxoSmithKline's...
-
Dec 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced its intention to restructure the Branded Consumer Healthcare's ("BCH") Omega Pharma Belgium business (which includes Omega Pharma Belgium NV,...
-
Nov 10, 2016
Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered...
-
Nov 10, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream...
-
Nov 10, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced the appointment of independent Directors Geoffrey M. Parker and Theodore R. Samuels to its Board of Directors, further enhancing its...
-
Nov 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on December 13, 2016 to shareholders of record on...
-
Oct 26, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its third quarter calendar year 2016 on Thursday, November 10, 2016 at approximately 6:30 a.m....
-
Sep 27, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the...
-
Sep 12, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today acknowledged receipt of a letter from Starboard Value LP, a Perrigo shareholder. Perrigo will review the letter carefully and looks forward to a...
-
Sep 7, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the Morgan Stanley Global Healthcare Conference at 11:05 AM EDT on...
-
Sep 1, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl...
-
Aug 23, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium...
-
Aug 17, 2016
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has agreed to acquire Peachtree City, Georgia-based, Geiss, Destin & Dunn, Inc. ("GDD"), a small national distributor of...
-
Aug 10, 2016
Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses* Delivered...
-
Aug 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International...
-
Aug 2, 2016
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on September 13, 2016 to shareholders of record on...
-
Jul 27, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2016 on Wednesday, August 10th, 2016 at approximately 6:00 a.m....
-
Jul 20, 2016Appoints John Wesolowski as Acting General Manager, Rx Pharmaceuticals
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the departure of Douglas Boothe,...
-
Jul 18, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg. This...
-
Jun 21, 2016
Perrigo Company plc (NYSE: PRGO; TASE), today announced it has received final U.S. Food and Drug Administration ("FDA") clearance for three milk-based, store brand non-GMO infant formulas....
-
Jun 20, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has reached a definitive agreement to sell its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin...
-
Jun 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' Ofirmev®...
-
Jun 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the 16th Annual Oppenheimer Consumer Conference at 9:05 AM EDT on...
-
Jun 13, 2016
Perrigo Company plc (NYSE: PRGO; TASE) announced that it has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for ingenol mebutate gel (0.015% and...
-
May 31, 2016
Perrigo Company plc (NYSE: PRGO; TASE) and its partner West-Ward Pharmaceuticals Corp. today announced the U.S. Food and Drug Administration has approved, and that Perrigo has launched,...
-
May 18, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the UBS Global Healthcare Conference at 1:30 PM EDT on Tuesday, May...
-
May 16, 2016- No changes to adjusted results or adjusted guidance from original earnings release issued on May 12, 2016
The full corrected release reads as follows: PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Delivered record first quarter adjusted net sales of $1.34 billion excluding VMS sales of
-
May 11, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter calendar year 2016 on Thursday, May 12, 2016 at approximately 6:00 a.m. (ET)....
-
May 3, 2016
Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets, the first OTC...
-
May 2, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Valeant Pharmaceutical International,...
-
Apr 28, 2016Announces Resignation of Marc Coucke as Executive Vice President and General Manager Branded Consumer Healthcare
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced that Mr. Sharon Kochan, Perrigo's...
-
Apr 26, 2016
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on June 14, 2016 to shareholders of record on May 27, 2016.
-
Apr 25, 2016Names Laurie Brlas as Chairman of the Board of Directors
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of John T. Hendrickson...
-
Apr 22, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today released the following statement regarding recent media coverage concerning Chairman and CEO Joseph C. Papa: "We are aware of the speculation regarding...
-
Apr 12, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced the first-to-market launch of the over-the-counter (OTC) store brand equivalent to Glucerna® aseptic adult nutritional shake for people with...
-
Mar 23, 2016
Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg extended-release tablets, the OTC store brand equivalent to Mucinex®...
-
Mar 16, 2016
Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), showcased eight new product SKUs at the 2016 Global Pet Expo: SENTRY® Vantaguard™ 2 and SENTRY® Flea & Tick Collar...
-
Mar 16, 2016
Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), showcased eight new product SKUs at the 2016 Global Pet Expo: PetArmor® Advanced 2 and PetArmor® Flea & Tick Collar...
-
Mar 10, 2016
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of the previously...
-
Mar 10, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the Barclays Global Healthcare Conference at 10:15 AM EST on Tuesday, March 15, 2016...
-
Mar 8, 2016
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the pricing of the previously...
-
Mar 7, 2016
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that Perrigo Finance Unlimited...
-
Mar 1, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the Cowen Annual Healthcare Conference at 4:00 PM EST on Monday, March 7, 2016 at the...
-
Feb 23, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the RBC Capital Markets Global Healthcare Conference at 8:00 AM EST on Wednesday,...
-
Feb 19, 2016DUBLIN HEADQUARTERS CENTRAL TO EUROPEAN & GLOBAL GROWTH STRATEGY
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), announced that a number of key public facing corporate functions will be relocated to Ireland as part of the Company's focused international...
-
Feb 18, 2016- Delivered record calendar year 2015 net sales of $5.35 billion, an increase of 28% compared to the prior year; with adjusted net income of $1.09 billion, an increase of 29% compared to the prior year; and adjusted earnings per share of $7.59, an increase of 21% compared to the prior year
Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the fourth quarter and calendar year ended December 31, 2015. Perrigo's Chairman and CEO Joseph C. Papa commented, "The team...
-
Feb 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on March 15, 2016 to shareholders of record on...
-
Feb 11, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will announce financial results for its calendar year and fourth quarter 2015 on Thursday, February 18, 2016 at approximately 6:00...
-
Jan 25, 2016- Acquires high barrier-to-entry assets that fit well within Perrigo's unique Rx extended topicals portfolio
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A®...